Quantitative Monitoring in the Era of Sugammadex
"We think that the continued misuse of both rocuronium and the blind administration of sugammadex is still associated with some serious postoperative [events]… If you have adequate monitoring, as we showed at the University of Iowa, you can eliminate that problem completely. Sugammadex does not make it go away."
-Dr. Michael Todd, Professor and Vice Chair of Research at University of Minnesota Medical Center
A recently published retrospective study from Vanderbilt University Medical Center supports Dr. Todd's statement. 10,491 eligible cases were examined and the odds of postoperative pulmonary complications in patients receiving sugammadex were no different than those receiving neostigmine.1
"TwitchView results in more targeted use of neuromuscular blocking agents (NMBAs) and precise doses of NMBA reversal agents2"
CONFIRMED
Patient Recovery
.png?width=79&name=iconfinder-128%20(1).png)
INFORMED
Drug Dosing
SUBMIT THE FORM
TO LEARN MORE.
Submit a request for more information and a representative will contact you shortly.
Contact us TODAY!
References: 1. Gen Li, Robert E. Freundlich, Rajnish K. Gupta, Christina J. Hayhurst, Chi H. Le, Barbara J. Martin, Matthew S. Shotwell, Jonathan P. Wanderer; Postoperative Pulmonary Complications’ Association with Sugammadex versusNeostigmine:A Retrospective Registry Analysis.AnesthesiologyNewly Published on March 17, 2021. 2. Ly N, Edwards LA, Morewood G. The influence of EMG-based quantitative TOF monitoring on clinical decision making. Paper presented at: Postgraduate Assembly in Anesthesiology; December 13-17, 2019; New York, NY.
